drugset / Trial / NCT04532346

Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes

NCT04532346

Phase 0 Recruiting 60 enrolled Children's Hospital of Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this proposed study is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) in children's interstitial lung diseases(chILD) with genetic causes. This study is a randomized controlled clinical trial.

Timeline

Start
2024-09-01
Primary completion
2026-10
Completion
2027-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 10 mg/kg Oral